451 related articles for article (PubMed ID: 10848876)
1. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
[TBL] [Abstract][Full Text] [Related]
2. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
Leroy I; d'Acremont M; Brailly-Tabard S; Frydman R; de Mouzon J; Bouchard P
Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
[TBL] [Abstract][Full Text] [Related]
3. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
[TBL] [Abstract][Full Text] [Related]
4. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
[TBL] [Abstract][Full Text] [Related]
5. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
6. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
[TBL] [Abstract][Full Text] [Related]
7. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
8. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study.
Olivennes F; Fanchin R; Bouchard P; Taïeb J; Selva J; Frydman R
Hum Reprod; 1995 Jun; 10(6):1382-6. PubMed ID: 7593501
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
[TBL] [Abstract][Full Text] [Related]
10. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.
Olivennes F; Fanchin R; Bouchard P; de Ziegler D; Taieb J; Selva J; Frydman R
Fertil Steril; 1994 Sep; 62(3):468-76. PubMed ID: 8062940
[TBL] [Abstract][Full Text] [Related]
11. [A study of the controlled ovarian hyperstimulation using GnRH agonist and pure FSH in in vitro fertilization-embryo transfer and gamete intrafallopian transfer program].
Usui A
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1431-8. PubMed ID: 2511261
[TBL] [Abstract][Full Text] [Related]
12. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge.
Fraser HM; Lunn SF; Morris KD; Deghenghi R
Hum Reprod; 1997 Mar; 12(3):430-5. PubMed ID: 9130734
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.
Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Niebch G; Derendorf H
Clin Pharmacol Ther; 2000 Dec; 68(6):617-25. PubMed ID: 11180022
[TBL] [Abstract][Full Text] [Related]
14. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
Paulson RJ; Sauer MV; Lobo RA
J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial.
Lee TH; Lin YH; Seow KM; Hwang JL; Tzeng CR; Yang YS
Fertil Steril; 2008 Jul; 90(1):113-20. PubMed ID: 18054932
[TBL] [Abstract][Full Text] [Related]
18. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
Ye H; Huang G; Pei L
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
[TBL] [Abstract][Full Text] [Related]
20. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
